xmab14045
mAbexperimentalMulti-specific
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02730312)
Timeline
Indications
Mechanism of action
- Interleukin-3 receptor subunit alphaINHIBITOR
IL3RA inhibitor
- T-cell surface glycoprotein CD3 epsilon chainImmunity, passive
CD3E immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4298131 ↗
Also known as
- xmab14045
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05285813 | Phase 2 | May 6, 2022 | University of Texas at Houston |
| NCT02730312 | Phase 1 | Aug 1, 2016 | Chiltern International, Xencor |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Chiltern International | For profit | 1 | 0 | 1 | 2016 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Xencor | For profit | 1 | 1 | 1 | 2016 |
3 organizations
Page 1 / 1